Case number IPR2022-00215
Hikma Pharmaceuticals USA Inc. et al. v. Amarin Pharmaceuticals Ireland Limited > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Nov 30, 2021 | 1 | petitioner | Petitioner's HIKMA Power of Attorney Download |
| Nov 30, 2021 | 1001 | petitioner | Ex. 1001 - U.S. Patent No. 8,642,077 B2 to Manku et al. Download |
| Nov 30, 2021 | 1002 | petitioner | Ex. 1002 - Expert Declaration of Edward A. Fisher, M.D., Ph.D., M.P.H. Download |
| Nov 30, 2021 | 1003 | petitioner | Ex. 1003 - WO 2007/142118 to Yokoyama et al. (2007) (certified English translation) Download |
| Nov 30, 2021 | 1004 | petitioner | Ex. 1004 - Mori et al., Purified Eicosapentaenoic and Docosahexaenoic Acids Have Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glucose, and Insulin in Mildly Hyperlipidemic Men, 71 Am. J. Clinical Nutri. 1085 Download |
| Nov 30, 2021 | 1005 | petitioner | Ex. 1005 - Yokoyama et al., Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): a Randomized Open- Label, Blinded Endpoint Analysis, 369 Lancet 1090 (2007) Download |
| Nov 30, 2021 | 1006 | petitioner | Ex. 1006 - Satoh et al., Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome, 30:1 Diabetes Care 144 (2007) Download |
| Nov 30, 2021 | 1007 | petitioner | Ex. 1007 - Grimsgaard et al., Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid in Humans Have Similar Triacylglycerol-Lowering Effects but Divergent Effects on Serum Fatty Acids, 66 Am. J. Clin. Nutr. 649 (1997) Download |
| Nov 30, 2021 | 1008 | petitioner | Ex. 1008 - Third Report of the National Cholesterol Education Program (N CEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111) Final Report (Sept. 2002) Part 3 Download |
| Nov 30, 2021 | 1008 | petitioner | Ex. 1008 -Third Report of the National Cholesterol Education Program (N CEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111) Final Report (Sept. 2002) Part 1 Download |
| Nov 30, 2021 | 1008 | petitioner | Ex. 1008 -Third Report of the National Cholesterol Education Program (N CEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111) Final Report (Sept. 2002) Part 2 Download |
| Nov 30, 2021 | 1009 | petitioner | Ex. 1009 - Plaintiffs' Corrected Post-Trial Proposed Findings of Fact and Conclusions of Law (Feb. 27, 2020) from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525, D.I. 377, 510 (D. Nev.) Download |
| Nov 30, 2021 | 1010 | petitioner | Ex. 1010 - Day 2 (Jan. 14, 2020) Trial Transcript from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) (Testimony of Dr. Budoff) Download |
| Nov 30, 2021 | 1011 | petitioner | Ex. 1011 -Vital and Health Statistics, Serum Lipids of Adults 20-74 Years: United States, 1976-80, 11:242, Nat'l Health Survey, U.S. Dept. Health & Human Servs. (Mar. 1993) Download |
| Nov 30, 2021 | 1012 | petitioner | Ex. 1012 - Schmidt et al., Lipid evaluation in HIV-1-positive patients treated with protease inhibitors, 4 Antiviral Ther. 163-170 (1999) Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 8 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 11 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 1 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 7 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 5 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 12 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 6 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 13 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 2 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 9 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 3 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 4 Download |
| Nov 30, 2021 | 1013 | petitioner | Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 10 Download |
| Nov 30, 2021 | 1014 | petitioner | Ex. 1014 - Lovaza, Physicians' Desk Reference 2699 (62d ed. 2007) Download |
| Nov 30, 2021 | 1015 | petitioner | Ex. 1015 - Nozaki et al., Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia, 62 Int'l J. Vitamin & Nutr. Res. 256- 60 (1992) Download |
| Nov 30, 2021 | 1016 | petitioner | Ex. 1016 - Shinozaki et al., The Long-Term Effect of Eicosapentaenoic Acid on Serum Levels of Lipoprotein (a) and Lipids in Patients with Vascular Disease, 2(2) J. Atheroscl. Thromb. 107-09 (1996) Download |
| Nov 30, 2021 | 1017 | petitioner | Ex. 1017 - Joint Stipulations of Fact from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Download |
| Nov 30, 2021 | 1018 | petitioner | Ex. 1018 - Day 7 (Jan. 28, 2020) Trial Transcript from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) (Testimony of Dr. Toth) Download |
| Nov 30, 2021 | 1019 | petitioner | Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 1 Download |
| Nov 30, 2021 | 1019 | petitioner | Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 4 Download |
| Nov 30, 2021 | 1019 | petitioner | Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 3 Download |
| Nov 30, 2021 | 1019 | petitioner | Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 2 Download |
| Nov 30, 2021 | 1020 | petitioner | Ex. 1020 -Plaintiffs' Infringement Contentions from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.) Download |
| Nov 30, 2021 | 1021 | petitioner | Ex. 1021 - Plaintiffs' Opposition to Motion to Dismiss from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.) Download |
| Nov 30, 2021 | 1022 | petitioner | Ex. 1022 - Plaintiffs' First Amended Complaint from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.) (D.I.17) Download |
| Nov 30, 2021 | 1023 | petitioner | Ex. 1023 - Exhibit U to Plaintiffs' First Amended Complaint,Ballantyne et al., Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides Download |
| Nov 30, 2021 | 1024 | petitioner | Ex. 1024 - Exhibit V to Plaintiffs' First Amended Complaint, Bhatt et al., Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, 380:1 N. Engl. J. Med. 11-22 (2018) Download |
| Nov 30, 2021 | 1025 | petitioner | Ex. 1025 -Amarin Response to U.S. Patent Office re U.S. Patent Application No. 17/768,906 (Aug. 26, 2013) Download |
| Nov 30, 2021 | 1026 | petitioner | Ex. 1026 - Davidson et al., Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients Download |
| Nov 30, 2021 | 1027 | petitioner | Ex. 1027 - Saito et al., Effects of EPA on Coronary Artery Disease in Hypercholesterolemic Patients with Multiple Risk Factors: Sub-Analysis of Primary Prevention Cases from the Japan EPA Lipid Intervention Study (JELIS) Download |
| Nov 30, 2021 | 1028 | petitioner | Ex. 1028 - Notice of Allowability from U.S. Patent Office re U.S. Patent Application No. 13/768,906 (Sept. 30, 2013) Download |
| Nov 30, 2021 | 1029 | petitioner | Ex. 1029 - FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting regarding ANCHOR trial (Oct. 16, 2013) Download |
| Nov 30, 2021 | 1030 | petitioner | Ex. 1030 -U.S. Patent Office Interview Summary re U.S. Patent Application No. 13/614,111 (Dec. 12, 2012) Download |
| Nov 30, 2021 | 1031 | petitioner | Ex. 1031 - Amarin Supplemental Response to U.S. Patent Office re U.S. Patent Application No. 13/614,111 (Jan. 11, 2013) Download |
| Nov 30, 2021 | 1032 | petitioner | Ex. 1032 - Notice of Allowability from U.S. Patent Office re U.S. Patent Application No. 13/614,111 (Feb. 11, 2013) Download |
| Nov 30, 2021 | 1033 | petitioner | Ex. 1033 - Vascepa Label (12/2019) Download |
| Nov 30, 2021 | 1034 | petitioner | Ex. 1034 - World Health Organization Memorandum, Classification of Hyperlipoproteinemias, 43:891, 501-508 (1972) Download |
| Nov 30, 2021 | 1035 | petitioner | Ex. 1035 - Declaration of C. Rosebraugh from Amarin Pharma, Inc. et al. v. U.S. F.D.A. et al., No. 15-3588 (S.D.N.Y.) Download |
| Nov 30, 2021 | 1036 | petitioner | Ex. 1036 - Scheduling Order from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.) Download |
| Nov 30, 2021 | 1037 | petitioner | Ex. 1037 - Hikma's Motion to Dismiss from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.) Download |
| Nov 30, 2021 | 1038 | petitioner | Ex. 1038 - Office Action from U.S. Patent Office re U.S. Patent Application No. 13/768,906 (May 24, 2013) Download |
| Nov 30, 2021 | 1039 | petitioner | Ex. 1039 -Original Japanese version of WO 2007/142118 to Yokoyama et al. Download |
| Nov 30, 2021 | 1040 | petitioner | Ex. 1040 - U.S. Patent No. 6,384,077 to Peet et al. Download |
| Nov 30, 2021 | 1041 | petitioner | Ex. 1041 - U.S. Patent No. 6,479,544 to Horrobin Download |
| Nov 30, 2021 | 1042 | petitioner | Ex. 1042 - U.S. Patent No. 7,119,118 to Peet et al. Download |
| Nov 30, 2021 | 1043 | petitioner | Ex. 1043 - Amarin Reports Fourth Quarter and Full Year 2004 Results Report Download |
| Nov 30, 2021 | 1044 | petitioner | Ex. 1044 - U.S. Patent Application Publication No. 2007/0021504 A1 to Yokoyama et al. Download |
| Nov 30, 2021 | 1045 | petitioner | Ex. 1045 - Yokoyama et al., Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS Download |
| Nov 30, 2021 | 1046 | petitioner | Ex. 1046 - Joint Claim Construction Chart from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.) Download |
| Nov 30, 2021 | 1047 | petitioner | Ex. 1047 - Curriculum vitae of Edward A. Fisher Download |
| Nov 30, 2021 | 1048 | petitioner | Ex. 1048 -Lipitor (atorvastatin calcium) Label (09/2007) Download |
| Nov 30, 2021 | 1049 | petitioner | Ex. 1049 - Crestor (rosuvastatin calcium) Label (11/2007) Download |
| Nov 30, 2021 | 2 | petitioner | IPR Petition '077 Download |
| Dec 14, 2021 | 3 | board | Notice: Notice filing date accorded Download |
| Mar 8, 2022 | 4 | patent_own | Patent Owner's Mandatory Notices Download |
| Mar 8, 2022 | 5 | patent_own | Patent Owner's Power of Attorney Download |
| Mar 10, 2022 | 6 | petitioner | Download |
| Mar 10, 2022 | 7 | petitioner | Joint Motion To Terminate Download |
| Mar 14, 2022 | 8 | board | Termination Decision: Settlement Prior to Institution of Trial Download |
| Mar 15, 2022 | 9 | petitioner | Petitioners' Request For Refund Of Post-Institution Fees Download |
| Mar 22, 2022 | 10 | board | Notice: refund approved Download |
